Tolerys SA is an early stage biotech company developing a novel anti-inflammatory immunotherapy named EFD BCG. This product is derived from BCG vaccine using a patented inactivation process.
Preclinical studies proved that EFD BCG relies on its unique capacity to induce regulatory T cells in several models of chronic inflammatory diseases and is associated with a favorable safety profile.
In parallel to preclinical R&D, Tolerys SA has developed EFD BCG's manufacturing process and is preparing a first-in-man clinical trial.
Domain: Therapeutics & Diagnostics, Other
Therapeutics & Diagnostics, Vaccines
Contact: Avenue de la Roseraie 64
1205 Geneva / GE
P: +41 22 372 38 01

http://www.tolerys.com
Find an actor

BioTaiwan 201819.07.2018

BioTaiwan Exhibition 2018 will be held from 19 to 22 July at the TWTC Nangang Exhibition Hall in Taipei, Taiwan.

GENOME JUMPER

Un jeu mobile pour explorer la diversité humaine.
Print this page Download this page (PDF) Recommend this page to a friend

Contact us

BioAlps Association
Ch. du Pré-Fleuri 3
CH - 1228 Plan-les Ouates
+41 22 304 40 40
+41 22 304 40 70

Subscribe to our newsletter

Find us on LinkedIn